Key clinical point: TP53 mutations detected by clinical laboratory mutation analysis (CLMA) can independently predict poor outcomes in patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL) treated with first-line immunochemotherapy.
Major finding: TP53 mutations significantly predicted disease progression at 2 years (adjusted hazard ratio 2.3; P = .03). Patients with vs without TP53 mutations had significantly lower overall response (71% vs 90%; P = .009), complete response (55% vs 77%, P = .01), estimated 2-year progression-free survival (57% vs 77%; P = .006), and estimated 2-year overall survival (70% vs 91%; P = .001) rates.
Study details: This study included 122 patients with newly diagnosed DLBCL or HGBL receiving first-line immunochemotherapy whose diagnostic biopsies underwent CLMA, of whom 42 patients had TP53 mutations.
Disclosures: This study did not disclose any funding source. All authors, except A Bagg, declared receiving honoraria, travel grants, or research funding from or having other ties with various sources.
Source: Landsburg DJ et al. TP53 mutations predict for poor outcomes in patients with newly-diagnosed aggressive B cell lymphomas in the current era. Blood Adv. 2023 (Oct 18). doi: 10.1182/bloodadvances.2023011384